Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic.

Slides:

Advertisements

Similar presentations

Regulation of human cytokines by Cordyceps militaris

Advertisements

Volume 75, Issue 1, Pages (January 2010)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Chlamydophila pneumoniae

Surgical removal of endometriotic lesions alters local and systemic proinflammatory cytokines in endometriosis patients Stephany P. Monsanto, M.Sc.,

The role of viruses in acute exacerbations of asthma

S. S. Pullamsetti, R. Savai, W. Janssen, B. K. Dahal, W. Seeger, F

In vitro functional comparison of therapeutically relevant human vasculogenic progenitor cells used for cardiac cell therapy Yan Zhang, MD, MSc, Serena.

Figure 1 The central role of chronic prostate

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 1 Associations between baseline cerebrospinal fluid

The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study Rachel K. Middleton, BSc,

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Identifying and Treating COPD in Cardiac Patients

Craig H Selzman, MD, Stephanie A Miller, MD, Alden H Harken, MD

Young and Aged Blunt Trauma Patients Display Major Differences in Circulating Inflammatory Mediator Profiles after Severe Injury Ashley J. Lamparello,

Change of proinflammatory cytokines follows certain patterns after induction of endometriosis in a mouse model Qiong-Hua Chen, Ph.D., Wei-Dong Zhou,

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

BALB/c scid mice have higher levels of macrophage-stimulating cytokines in circulation compared with BALB/c control mice. BALB/c scid mice have higher.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Y. -P. Ding, M. -F. Liang, J. -b. Ye, Q. -h. Liu, C. -h. Xiong, B

Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.

Unstimulated levels of soluble mediators from in cultures of individuals with and without T2D with periodontitis. Unstimulated levels of soluble mediators.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 2 Concordance of results for commercial cell-based assay (CBA) and fluorescence-activated cell sorting (FACS) assays, FACS titers, and disease activity.

Figure 3 sVEGF concentrations in anemia and hypoxemic diseases

Figure 2 CD4+ and CD8+ T cells accumulate in the CSF in GABAB receptor antibody–associated LE CD4+ and CD8+ T cells accumulate in the CSF in GABAB receptor.

Holger Lawall, MD, Peter Bramlage, MD, PhD, Berthold Amann, MD

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 3 Hypothesized cellular and molecular crosstalk influencing NMO/SD Hypothesized cellular and molecular crosstalk influencing NMO/SD (A) Theoretical.

Romain Gallet et al. BTS 2016;1:14-28

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 3 Longitudinal performance of 2 MS–cohabitant participant pairs on Ishihara color testing Both response speed and response accuracy are provided.

Figure 2 Immune changes in peripheral blood of pregnant patients with NMO Immune changes in peripheral blood of pregnant patients with NMO (A) Interleukin.

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.

Figure 2 Reduced frequency of central memory CD4 T cells in patients with PML Reduced frequency of central memory CD4 T cells (CD4Tcm) (p < ), naive.

Figure 3 Cytokine gene expression in PBMC stimulated with PPD or MBP in vitroCytokine messenger RNA transcripts were isolated from peripheral blood mononuclear.

Figure 1 B cells and plasma cells accumulate in the CSF in GABAB receptor antibody–associated LE B cells and plasma cells accumulate in the CSF in GABAB.

Figure 1 Examples illustrating gating strategy for fluorescence-activated cell sorting (FACS)‏ Examples illustrating gating strategy for fluorescence-activated.

Figure 1 Association between serum levels of IL-18 and hippocampal volume in patients with schizophrenia Scatter plots show a positive correlation between.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Schematic illustration of the concepts in the pathogenesis of rheumatoid arthritis associated-interstitial lung disease (RA-ILD). Schematic illustration.

Angiogenesis and arteriogenesis in limb ischemia

Figure 2 Correlation of CSF 8-iso-PGF2α levels with other indicators of oxidative stressCorrelations of 8-iso-prostaglandin F2α (8-iso-PGF2α) values with.

Figure 4 Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid.

Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis.

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Figure 1 Levels of miR-150 are elevated in patients with multiple sclerosis (MS) and patients with clinically isolated syndrome (CIS) who convert to MS.

Figure 2. Odds ratios (ORs) from the multivariate logistic regression analysis and hazard ratios (HRs) from the Cox regression analysis Odds ratios (ORs)

Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression The N:M ratio is significantly increased.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure 2 Glatiramer acetate treatment induced M2 differentiation through a MyD88-independent pathway (A) As described previously,3 M2 monocytes were treated.

Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.

Figure 3 Impact of short-term MP administration on frequency and phenotype of slanDCs and monocytes in the blood of patients with MSThe percentages of.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Figure 1 Classical pathway and lectin pathway activity in patients with multifocal motor neuropathy and controls Classical pathway (CP) activity (A) and.

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Figure 2 Detection of atypical anti-neuronal antibodies Immunohistofluorescence assay on rat brain sagittal slices incubated with the patient's CSF and.

Figure 3 Fingolimod inhibits TNF-α secretion by human monocytes Peripheral blood mononuclear cells from healthy donors were briefly exposed to increasing.

Yian Gu et al. Neurol Neuroimmunol Neuroinflamm 2019;6:e521

Ingo Kleiter et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e504

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 2 Detection of slanDCs in CSF of patients with MS(A, B) Immunocytochemical stainings were performed to determine the presence of 6-sulfo LacNAc+

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS (B) during the mean study period of.

Presentation transcript:

Figure 1 Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic diseases (ONDs, n = 10), multifocal motor neuropathy (MMN, n = 12), progressive muscular atrophy (PMA, n = 8), and amyotrophic lateral sclerosis (ALS, n = 26).*p < 0.05, **p < 0.01. Cytokine titers determined by the multiplex bead assay Plotted are cytokine titers (pg/mL) in CSF of patients with other noninflammatory neurologic diseases (ONDs, n = 10), multifocal motor neuropathy (MMN, n = 12), progressive muscular atrophy (PMA, n = 8), and amyotrophic lateral sclerosis (ALS, n = 26).*p < 0.05, **p < 0.01. FGF-2 = fibroblast growth factor-2; G-CSF = granulocyte colony-stimulating factor; IL = interleukin; IL-1ra = IL-1 receptor antagonist; IP-10 = interferon-γ–induced protein 10; MCP-1 = monocyte chemotactic protein-1; PDGF-BB = platelet-derived growth factor BB; TNF-α = tumor necrosis factor α; VEGF = vascular endothelial growth factor. Takahiro Furukawa et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e138 © 2015 American Academy of Neurology